Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05855200 · ClinicalTrials.gov registry record · Phase 3

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

A Phase 3 study of Colonic Neoplasms and Neoplasms, Colon, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 3
Development phase
892
Enrollment target
20
Study locations

NCT05855200 is a Phase 3 study of Colonic Neoplasms and Neoplasms, Colon that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 892 participants, below the 1,459-participant average among 14 other Colonic Neoplasms trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05855200, a Phase 3 study of Colonic Neoplasms and Neoplasms, Colon, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 3
Development phase
892 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.

Conditions Studied

Colonic Neoplasms Neoplasms, Colon

Interventions

  • DRUG FOLFOX
  • BIOLOGICAL Dostarlimab
  • DRUG CAPEOX

Study Locations (20)

Illinois

  • GSK Investigational Site - Chicago
  • GSK Investigational Site - Chicago
  • GSK Investigational Site - Chicago
  • GSK Investigational Site - Naperville
  • GSK Investigational Site - Naperville

Florida

  • GSK Investigational Site - Deerfield Beach
  • GSK Investigational Site - Fort Lauderdale

Kentucky

  • GSK Investigational Site - Lexington
  • GSK Investigational Site - Louisville

Michigan

  • GSK Investigational Site - Ann Arbor
  • GSK Investigational Site - Detroit

Arizona

  • GSK Investigational Site - Tucson

California

  • GSK Investigational Site - Los Angeles

Connecticut

  • GSK Investigational Site - New Haven

District of Columbia

  • GSK Investigational Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 892 participants
Start Date 2023-08-01
Est. Completion 2031-03-27
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05855200

The ClinicalTrials.gov registry entry for NCT05855200 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 892 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,459-participant average among 14 other Colonic Neoplasms trials with a reported enrollment target (39% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Colonic Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which FOLFOX is the first listed.

NCT05855200 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Illinois, Florida, Kentucky.

Frequently Asked Questions

What is clinical trial NCT05855200 about?

NCT05855200 is a clinical study titled "Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer". The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.

What is the current status of trial NCT05855200?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 892 participants. The study started on 2023-08-01. Estimated completion is 2031-03-27.

What conditions does trial NCT05855200 study?

This clinical trial studies the following conditions: Colonic Neoplasms, Neoplasms, Colon.

What interventions are being tested in trial NCT05855200?

The interventions under investigation include: FOLFOX (DRUG), Dostarlimab (BIOLOGICAL), CAPEOX (DRUG).

Who is sponsoring clinical trial NCT05855200?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05855200 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colonic Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colonic Neoplasms

All registered trials for this condition

Neoplasms, Colon

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.